Prolonged remission maintenance in acute myeloid leukaemia.
- 27 August 1977
- Vol. 2 (6086), 544-547
- https://doi.org/10.1136/bmj.2.6086.544
Abstract
Twenty-five patients with acute myeloid leukaemia were treated with three quadruple drug combinations in predetermined rotation: TRAP (thioguanine, daunorubicin, cytarabine, prednisolone); COAP (cyclophosphamide, vincristine, cytarabine, prednisolone); and POMP (prednisolone, vincristine, methotrexate, mercaptopurine). Fifteen patients (60%) achieved complete remission and five (20%) partial remission. For maintenance, five-day courses of drugs were administered every 14 to 21 days and doses were increased to tolerance. The median length of complete remission was 66 weeks. In eight patients remission maintenance treatment was discontinued and some remained in complete remission for over two years. In this series the remission induction rate was comparable with that reported for other regimens and complete remission lasted longer with this intensive maintenance regimen than with others. Nevertheless, the TRAP programme must still be regarded as only palliative treatment for acute myeloid leukaemia.Keywords
This publication has 14 references indexed in Scilit:
- Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patientBritish Journal of Cancer, 1977
- QUALITY AND QUANTITY OF SURVIVAL IN ACUTE MYELOID LEUKÆMIAThe Lancet, 1975
- CHEMOIMMUNOTHERAPY OF ADULT ACUTE LEUKÆMIA PROLONGATION OF REMISSION IN MYELOBLASTIC LEUKÆMIA WITH B.C.G.The Lancet, 1974
- Management of Adult Acute Myelogenous LeukaemiaBMJ, 1973
- Acute myelocytic leukemia in adultsCancer, 1972
- Treatment of the acute leukemias.1972
- Five-year follow-up of "total therapy" of childhood lymphocytic leukemia.1971
- Drug dosage and remission duration in childhood lymphocytic leukemiaCancer, 1971
- Combination Chemotherapy using L-Asparaginase, Daunorubicin, and Cytosine Arabinoside in Adults with Acute Myelogenous LeukaemiaBMJ, 1970
- DAUNORUBICIN IN THE TREATMENT OF ACUTE MYELOCYTIC LEUKÆMIAThe Lancet, 1969